Millendo Therapeutics acquires Alizé Pharma

NewYear
Merry Christmas and Happy New year 2018
21 December 2017
Pavé newletter
December 2017 newsletter
4 December 2017

Millendo Therapeutics acquires Alizé Pharma

AlizeePharma_actu

The clinical-stage company focused on novel treatments for endocrine diseases will develop Alizé’s livoletide (AZP-531) for PWS.